Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dorchester Minerals

Momentus

Goldman Sachs Physical Gold ETF

Invesco DB Gold Fund

DB Gold Double Long ETN

SPDR Gold Trust

SPDR Gold MiniShares Trust

iShares Gold Trust

iShares Gold Strategy ETF

VanEck Merk Gold Trust

ProShares Ultra Gold

Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023.

Gold Price Alert: Gold Spot Prices Just Hit a Record High Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for Seres as we launched our first-in-class oral microbiome therapeutic, VOWST, for recurrent CDI into commercialization with our collaborators at Nestlé Health Science,” said Eric Shaff, President and Chief Executive Officer of Seres. “We are proud of th.

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast,.

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres' website. A replay of the presentation will bec.

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both p.

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica.

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after.

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteria.

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archi.

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

Apollo Global Management

Brookfield Asset Management

Blackstone Group

Equitrans Midstream

Fiserv Inc

General Mills

Alphabet

IAC/InterActiveCorp

loanDepot

Match Group

Ferrari

Stellantis N.V. 

Teladoc

TC Energy

TransUnion

While 2014 was a then-record year for initial public offerings (IPOs), 2015 was the worst since 2009 measured by cash raised.

15 Companies That Had Their IPO in 2015: Best and Worst Performers

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Stephen Sloan - Goldman Sachs Operator Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued progress, driven by a significant increase in new patient starts and exceeding the Company's forecasted expectations across multiple dimensions. VOWST is indicated to prevent the recurrence of Cl.

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET. The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference cal.

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023), including two posters of post-hoc analyses from the ECOSPOR III and ECOSPOR IV Phase 3 trials, which supported the recent approval by the US Food and Drug Administration (FDA) of VOWST as the first orally-administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (rCDI) i.

Seres Therapeutics to Highlight VOWST™ Data at IDWeek

Denali Therapeutics

Foghorn Therapeutics

Moderna

Omega Therapeutics

Sana Biotechnology

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will b.

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Therapeutics' partnership with Nestle provides financial backing and distribution support, highlighting the potential of its drug VOWST.

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President and CEO Lisa von Moltke - EVP and Chief Medical Officer Terri Young - Chief Commercial Officer David Arkowitz - EVP, CFO and Head of Business Development Matthew Henn - Chief Scientific Officer Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.

Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript

Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.

Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2023 financial results and provided business updates. “Seres achieved a major corporate milestone during the second quarter with the FDA approval of VOWST, the first and only FDA-approved orally administered microbiome therapeutic for the treatment of adult recurrent C. difficile infection patients, including those with first recurrence,” said Eric.

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Seres and Nestlé launched the first oral drug to prevent recurrence of Clostridioides difficile infection (CDI). CDI treatment wrings high costs from the healthcare system and individual patients, ensuring broad insurance coverage in the next few months. There is little current competition and no apparent rivals lurking in the space for the near future.

Seres Therapeutics: VOWST's Time To Shine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4844622. To join the live webcast, please visit the.

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 3:00 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for.

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world. Seres was included within the ‘Pioneers' category. To develop the list, TIME solicited company nominations from multiple sectors from its editors and correspondents, as well as from industry experts. TIME editors selected 100 leading companies fol.

Seres Therapeutics Named to TIME100 Most Influential Companies List

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

News for Seres Therapeutics Stock (MCRB)